Compare Davita Inc (DVA) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nomura Holdings Inc — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while Nomura Holdings Inc trades at $9.59 (market cap $27.55B). The key difference: Nomura Holdings Inc is far larger — about 2.4× Davita Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Nomura Holdings Inc for 55 Days on average.
| DVA | NMR | |
|---|---|---|
Market Cap | $11.29B | $27.55B |
Volume | 582,204 | 782,470 |
Sector | Health | Financials |
52-Week High | $240.96 | $10.86 |
52-Week Low | $103.87 | $6.73 |
Typical Hold Time | 114 Days | 55 Days |
Enterprise Value | $24.01B | $38.54T |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
Nomura Holdings (NMR) trades at $9.54, up 0.1% on the day, with a bearish technical signal but strong fundamental metrics including a P/E of 11.33 and net income margin of 20.4%. Recent earnings show a mix of beats and misses, while cash flow trends indicate significant financing activity. The stock is near its support level of $9, with RSI indicators suggesting potential oversold conditions. Zacks Research highlighted NMR as a strong buy for momentum and value in September 2026, citing recent price strength.
The outlook for NMR is cautiously optimistic, supported by solid profitability and valuation, but tempered by bearish technicals and inconsistent earnings performance. Key risks include high debt levels and macroeconomic sensitivity, while analyst sentiment leans hold. Upside potential exists if earnings stabilize and technical support holds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
